David Kelsen, MD
Enriched profileEdward S. Gordon Chair in Medical Oncology · Memorial Sloan Kettering Cancer Center
David Kelsen is Edward S. Gordon Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 481 publications with 23,055 citations (h-index 87); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
David Kelsen, MD, is Edward S. Gordon Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center. The public record shows 481 publications with 23,055 citations (h-index 87), centered on Gastric Cancer Management and Outcomes, Pancreatic and Hepatic Oncology Research, Esophageal Cancer Research and Treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies, 6 NIH-funded awards (1985–2011).
- Most recent indexed publication: 2023 · JMIR public health and surveillance
- Top research focus: Gastric Cancer Management and Outcomes
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 235.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Attending Physician
Gastrointestinal Oncology Service
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
- Early Onset and Familial Gastric Cancer Registry
Sponsor: Memorial Sloan Kettering Cancer Center
- Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery
Sponsor: Radiation Therapy Oncology Group
Industry payments
Updated 16 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20244 payments
- E.R. Squibb & Sons, L.L.C.Program year20242 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
59.6%Proton pump inhibitor36.8%Pantoprazole Sodium100%Part D<11 patientsCorticosteroid22.8%Prednisone100%Part D<11 patientsBlood & clotting
21.1%Factor Xa inhibitor21.1%Xarelto100%Part D<11 patientsNervous system
19.3%Opioid Agonist19.3%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
6 NIH research awards on record, funded 1985–2011 per NIH RePORTER. The latest:
- Early Therapeutics Development with Phase II Emphasis
Sloan-Kettering Inst Can Research
FY2011$377,050N01CM62206 - Early Therapeutics Development with Phase II Emphasis
Sloan-Kettering Inst Can Research
FY2010$346,045N01CM62206 - TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8461
Sloan-Kettering Inst Can Research
FY2009$2,227,911N01CM62206
Congress activity
Updated 16 Oct 2026
96 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Clinico-genomic characterization of PALB2 -mutated pancreatic adenocarcinoma.
ASCO Annual Meeting
ASCO2025Co-author - Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)
AACR (meeting unresolved)
AACR2024Co-author - Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer
AACR (meeting unresolved)
AACR2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study.
JMIR public health and surveillance
Article2023 - Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers.
Nature communications
Article2023 - Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice.
Clinical cancer research
Article2022
Most-cited works
by citation count (OpenAlex)- 01Extracellular Vesicle and Particle Biomarkers Define Multiple Human CancersArticle1,242 citations2020
- 02
- 03
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-kelsen-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Co-chair
Clinical Trials Subcommittee, Lustgarten Foundation for Pancreatic Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Member
Research Council, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH